Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Vermont
With
National Institute on Drug Abuse (NIDA)
E-cigarettes with nicotine can affect important cardiopulmonary outcomes and likely pose less risk than cigarettes, but they are not harmless. Given the existing literature, there is a need for controlled trials of e-cigarette use in populations with cardiopulmonary disease to fill the gaps between these existing examinations. Clarifying how the pulmonary and cardiac effects of e-cigarettes compare to use of conventional cigarettes in those with cardiopulmonary disease beyond single acute exposures will provide important new health information that can help inform policy.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women 40 years of age or older
Current, every day smoker (5 or more cigarettes per day for one year or longer) confirmed with intake CO of 8ppm or greater
Established pulmonary disease (chronic obstructive pulmonary disease \[COPD\], chronic bronchitis, emphysema, or asthma-COPD overlap syndrome) confirmed by physician diagnosis and/or current prescription of medication for treatment (i.e., LABA, LAMA, +/- ICS, or combination)
Lives and plans to remain in the greater Burlington, VT area for the next month
No intention to quit smoking within the next month
Speaks English
You may not be if
Patients who are medically unstable (unstable symptoms, changes in medications or hospitalizations within last 3 months)